BICYCLE THERAPEUTICS PLC Income Statement
BCYC|7 years of annual SEC 10-K data (FY2019-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
BICYCLE THERAPEUTICS PLC reported $73M in revenue and $219M in net loss for FY2025. Revenue has grown at a 81.1% compound annual rate over the past 6 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.98 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $72.6M | $35.3M | $27.0M | $10.4M | $13.8M | $7.1M | $2.1M |
| SG&A Expense | $79.4M | $72.2M | $60.4M | $29.2M | $14.6M | $8.1M | $6.4M |
| R&D Expense | $240.3M | $173.0M | $156.5M | $33.1M | $25.5M | $20.8M | $11.9M |
| Operating Income | -$247.1M | -$209.9M | -$189.9M | -$52.0M | -$26.3M | -$21.7M | -$16.2M |
| Interest Expense | - | - | $3.3M | $457.0K | $457.0K | $457.0K | - |
| Income Tax | $152.0K | -$4.8M | $1.5M | -$724.0K | -$254.0K | -$396.0K | -$23.0K |
| Net Income | -$219.0M | -$169.0M | -$180.7M | -$51.0M | -$30.6M | -$21.8M | -$16.3M |
| EPS (Basic) | -$5.08 | -$3.80 | -$2.67 | -$2.66 | -$2.77 | - | - |
| EPS (Diluted) | -$5.08 | -$3.80 | -$2.67 | -$2.66 | -$2.77 | -$49.78 | -$48.81 |
| Shares Outstanding | 69.1M | 42.4M | 29.9M | 29.6M | 21.1M | 18.0M | 814.7K |
| Operating Margin | -340.4% | -595.0% | -704.1% | -500.1% | -190.6% | -304.7% | -787.0% |
| Profit Margin | -301.7% | -479.2% | -669.7% | -491.0% | -221.8% | -306.1% | -789.3% |